GT Biopharma, Inc.
GTBP Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$5.46
KIRA · Stoqly’s AI analyst, in plain words
- GT Biopharma, Inc. lost $28.4M in fiscal 2025.
- GT Biopharma, Inc. returned $0.2M to shareholders in fiscal 2025. The diluted share count rose 190.6%.
Market cap
$212M
P/E
1.3x
Revenue
—
Net income
−$28.4M
Free cash flow
—
Operating margin
—
GT Biopharma, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$28.4M
No. It lost money last year.
How is the share priced?
1.3x
One share costs 1.3 times its yearly profit per share.
What GT Biopharma, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 2, 2026
- Legal name
- GT Biopharma, Inc.
- CIK
- 0000109657
GT Biopharma, Inc. · GTBP
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Net income | −$58.0M | −$20.9M | −$7.6M | −$13.2M | −$28.4M |
| Diluted EPS | −$2.06 | −$19.66 | −$5.64 | −$6.94 | −$6.68 |
| Cash | |||||
| Cash from operations | −$15.6M | −$15.2M | −$8.9M | −$12.9M | −$12.9M |
| Dividends paid | — | — | — | — | $0.2M |
| Share count change | 542.1% | −96.2% | 26.9% | 40.8% | 190.6% |
| Debt and strength | |||||
| Cash and short-term investments | $32.0M | $16.5M | $14.0M | $4.0M | $6.8M |
| Shareholders' equity | $21.9M | $11.7M | $7.5M | −$1.7M | $5.8M |
| Current ratio | 3.1x | 3.4x | 2.1x | 0.7x | 3.5x |
| Interest coverage | −80.1x | −2,657.1x | −63.7x | — | −97.8x |
| Returns and quality | |||||
| Return on equity | — | −124.1% | −79.1% | −453.4% | −1,377.4% |
| Return on tangible equity | −264.8% | −178.0% | −101.6% | — | −595.3% |
| Altman Z'' | −71.5 | −132.9 | −159.4 | −561.2 | −294.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
GT Biopharma, Inc. · GTBP
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $5.46 a share, the company is worth $212M: 1.3 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0000109657). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.